Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
  • inderesTV
  • Portfolio
  • Forum
  • Premium
  • Femme
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team
Press release

Qlife Holding AB: Qlife has successfully verified the biomarkers related to the previously announced LOI

Qlife Holding

Qlife is pleased to announce that, in collaboration with Hipro Biotechnology, the company has successfully verified biomarkers related to the LOI with a top-20 global pharma company that was announced on January 28th.  

On 28 January 2025, Qlife signed a Letter of Intent (LOI) with a top-20 global pharmaceutical company to explore potential commercial collaborations. Among the key criteria outlined in the LOI was Qlife's ability to test and integrate specific biomarkers into the Egoo Health platform. The company has now successfully verified these biomarkers, generating positive data. This confirmation demonstrates that the biomarkers covered in the LOI are compatible with the Egoo Health platform, reinforcing the feasibility of their integration.

"We look forward to presenting these data and expect that this will further advance discussions toward a partnership. As always, further validation of the biomarkers is required, and other parameters still need to be confirmed. However, it is very positive that the biomarkers have been fundamentally proven on the platform."- says Thomas Warthoe, CEO Qlife.

Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.